Nvidia dives deeper into AI drug development with Amgen, Recursion partnerships 

Nvidia is doubling down on artificial-intelligence-powered drug discovery and development, announcing expanded partnerships with Amgen and Recursion Pharmaceuticals.

Previous post Good news for tenants: Rents have fallen for three months in a row
Next post Bank of America to take $1.6 billion noncash charge as it transitions away from BSBY index for lending